Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVO101 · 2 trials · 2 indications
EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.
The change in the total HS lesion count will be assessed at Week 4, Week 8, and Week 12. The percent change from Baseline will be calculated.
| Arm | Type | Description |
|---|---|---|
| EVO101 Cream | EXPERIMENTAL | Active Treatment, BID, 8 weeks |
| Vehicle Cream | PLACEBO_COMPARATOR | Vehicle Treatment, BID, 8 weeks |
| Open label EVO101 topical cream 0.1% | EXPERIMENTAL | All eligible subjects will receive open label EVO101 topical cream 0.1% |
| Name | Type | Description |
|---|---|---|
| EVO101 | DRUG | Topical Cream |
Inclusion Criteria: 1. Males or non-pregnant, non-lactating females, age 18 years or older 2. Chronic atopic dermatitis for at least 1 year 3. IGA score of 2 or 3 4. BSA of AD involvement of 4-12% 5. EASI of 5-20 Exclusion Criteria: 1. Significant AD flare with 4 weeks 2. Use of biologic therapy ...
EVO101 is an investigational small molecule being developed for dermatology conditions, specifically atopic dermatitis (eczema) and hidradenitis suppurativa (HS). It is being studied as a topical cream formulation. EVO101 is not FDA approved and remains in clinical development.
EVO101 targets IRAK4, an enzyme involved in inflammatory signaling pathways. By inhibiting IRAK4, EVO101 is designed to modulate inflammation relevant to skin conditions like atopic dermatitis and hidradenitis suppurativa. The drug is administered as a topical cream.
EVO101 is being developed by Evommune, Inc., a biopharmaceutical company. Evommune is publicly traded under the ticker symbol EVMN. The company is conducting clinical trials to evaluate EVO101 for dermatological indications.
EVO101 is in Phase 2 clinical development for atopic dermatitis, based on a completed Phase 2 trial. An additional early Phase 1 trial for hidradenitis suppurativa is currently recruiting participants. EVO101 is investigational and has not received FDA approval.
EVO101 has been studied in two clinical trials. NCT05579899 was a completed Phase 2 trial evaluating EVO101 topical cream in 119 participants with atopic dermatitis. NCT06645821 is an early Phase 1 trial currently recruiting 15 participants with hidradenitis suppurativa in the United States.
EVO101 is being studied as a topical cream 0.1% for hidradenitis suppurativa in an early Phase 1 trial (NCT06645821). This trial is recruiting 15 adult participants in the United States. The same drug is also being evaluated for atopic dermatitis in a separate Phase 2 study.